Welcome to our dedicated page for Disc Medicine SEC filings (Ticker: IRON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Disc Medicine filings document the regulatory and financial record of a clinical-stage biopharmaceutical company developing hematologic disease therapies. Its Form 8-K disclosures cover quarterly and annual financial results, corporate updates, clinical-program materials for bitopertin, DISC-0974 and DISC-3405, and FDA communications related to the bitopertin New Drug Application for erythropoietic protoporphyria.
The filing record also includes proxy materials covering board matters, executive compensation and shareholder voting items. Material-event reports describe Regulation FD presentations, operating runway disclosures, restructuring actions following regulatory developments, and risk-related statements around clinical trials, regulatory pathways, research spending and capital resources.
Disc Medicine, Inc. (IRON) – Form 4 insider transaction
Chief Financial Officer Jean M. Franchi disclosed the sale of 2,000 common shares on 07/10/2025 at $57.50 per share, for proceeds of roughly $115 thousand. The transaction was executed under a Rule 10b5-1 trading plan adopted on 03/10/2025, indicating it was pre-scheduled rather than discretionary. After the sale, Franchi retains 65,530 shares, a decrease of about 3% of her direct holdings, maintaining a sizable equity position that continues to align her interests with shareholders. No derivative securities acquisitions or dispositions were reported in this filing.
Disc Medicine, Inc. (Nasdaq: IRON) has filed a Form 8-K announcing the election of Nadim Ahmed to its Board of Directors, effective 14 July 2025. Ahmed will serve as a Class I director until the company’s 2027 annual meeting and thereafter until a successor is elected or he resigns. Under the company’s non-employee director compensation policy, he will receive $40,000 in annual cash fees (paid $10,000 quarterly) and a non-statutory option for 20,000 shares of common stock priced at the market close on the effective date. The option vests one-third on the first anniversary and the balance in equal monthly installments over the next two years, contingent on continued service. The filing notes no related-party transactions involving Ahmed and states he will enter into the standard director indemnification agreement. No other material financial or operational disclosures were provided.
Disc Medicine, Inc. (IRON) – CEO Form 4 filing dated 07/08/2025
Chief Executive Officer John D. Quisel disclosed an exercise-and-sell transaction executed on 07/03/2025 under a Rule 10b5-1 trading plan adopted on 02/13/2025.
- Option exercise (Code M): 5,200 options exercised at $9.86, converting into 5,200 common shares.
- Open-market sale (Code S): the same 5,200 shares sold at a $55.0874 weighted-average price (range $55.00–$55.26), generating ≈ $0.29 million gross proceeds.
- Post-transaction ownership: 161,828 common shares held directly and 150,175 options remaining.
- The underlying option grant (09/13/2031 expiration) vests in 48 equal monthly tranches that began on 09/01/2021.
The filing represents a relatively small (< 4%) reduction in Quisel’s equity stake and appears routine, given the pre-arranged 10b5-1 plan. No company fundamentals were released.